AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson’s disease

  • MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson’s disease by targeting restorative sleep mechanisms
  • Parkinson’s UK-funded research with University College London (UCL) will further explore the link between enhanced slow-wave sleep and glymphatic flow, the brain’s natural waste-clearance mechanism

London, UK, 22 September 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel therapeutics for Alzheimer’s disease and other neurological disorders by improving sleep architecture, today announces that it has received funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and that Parkinson’s UK is funding an additional complementary research effort in collaboration with University College London (UCL).

Read more…

© Optimum Strategic Communications.